Literature DB >> 15701880

The molecular pharmacology of estrogen receptor modulators: implications for the treatment of breast cancer.

Donald P McDonnell1.   

Abstract

In addition to physiologic activities in the reproductive, skeletal, and central nervous systems, estrogens have been shown to play important roles in the aberrant cell proliferation observed in breast and reproductive tract cancers. Not surprisingly, pharmaceuticals that target different steps in the estrogen signal transduction pathway have found widespread use in the treatment of a wide variety of estrogen-linked disorders. The goal of this review is to outline what is known about the molecular pharmacology of the estrogen receptor and discuss how this information can be used to guide selection of drugs for a particular therapeutic application, and identify new targets where pharmaceutical exploitation could yield novel therapeutics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15701880

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  16 in total

1.  Differential recruitment of co-regulatory proteins to the human estrogen receptor 1 in response to xenoestrogens.

Authors:  L Cody Smith; Jessica C Clark; Joseph H Bisesi; P Lee Ferguson; Tara Sabo-Attwood
Journal:  Comp Biochem Physiol Part D Genomics Proteomics       Date:  2016-04-20       Impact factor: 2.674

2.  Ligand binding to the androgen receptor induces conformational changes that regulate phosphatase interactions.

Authors:  Chun-Song Yang; Hong-Wu Xin; Joshua B Kelley; Adam Spencer; David L Brautigan; Bryce M Paschal
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

Review 3.  Skeletal and gene-regulatory functions of nuclear sex steroid hormone receptors.

Authors:  Akira Hayakawa; Tomohiro Kurokawa; Yoshiaki Kanemoto; Takahiro Sawada; Jinichi Mori; Shigeaki Kato
Journal:  J Bone Miner Metab       Date:  2022-01-25       Impact factor: 2.626

4.  Application of screening methods, shape signatures and engineered biosensors in early drug discovery process.

Authors:  Izabela Hartman; Alison R Gillies; Sonia Arora; Christina Andaya; Nitya Royapet; William J Welsh; David W Wood; Randy J Zauhar
Journal:  Pharm Res       Date:  2009-07-22       Impact factor: 4.200

5.  Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma.

Authors:  Galina Lurie; Lynne R Wilkens; Pamela J Thompson; Katharine E McDuffie; Michael E Carney; Keith Y Terada; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2008-08-15       Impact factor: 2.506

6.  Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance.

Authors:  Fuxiao Xin; Meng Li; Curt Balch; Michael Thomson; Meiyun Fan; Yunlong Liu; Scott M Hammond; Sun Kim; Kenneth P Nephew
Journal:  Bioinformatics       Date:  2008-12-17       Impact factor: 6.937

7.  Cleaved thioredoxin fusion protein enables the crystallization of poorly soluble ERalpha in complex with synthetic ligands.

Authors:  Vincent Cura; Monique Gangloff; Sylvia Eiler; Dino Moras; Marc Ruff
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2007-12-20

8.  Utilizing the estrogen receptor ligand-binding domain for controlled protein translocation to the insoluble fraction.

Authors:  James R Davis; Mohanad Mossalam; Carol S Lim
Journal:  Pharm Res       Date:  2012-08-07       Impact factor: 4.200

9.  Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.

Authors:  Mathilde S Larsen; Karsten Bjerre; Anne E Lykkesfeldt; Anita Giobbie-Hurder; Anne-Vibeke Laenkholm; Katrine L Henriksen; Bent Ejlertsen; Birgitte B Rasmussen
Journal:  Breast       Date:  2012-07-31       Impact factor: 4.380

10.  Estrogen and sex-dependent loss of the vocal learning system in female zebra finches.

Authors:  Ha Na Choe; Jeevan Tewari; Kevin W Zhu; Matthew Davenport; Hiroaki Matsunami; Erich D Jarvis
Journal:  Horm Behav       Date:  2021-01-23       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.